Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,754,056
  • Shares Outstanding, K 211,176
  • Annual Sales, $ 1,978 M
  • Annual Income, $ 83,590 K
  • EBIT $ 486 M
  • EBITDA $ 707 M
  • 60-Month Beta 0.66
  • Price/Sales 5.51
  • Price/Cash Flow 16.43
  • Price/Book 3.21

Options Overview Details

View History
  • Implied Volatility 33.91% (-12.04%)
  • Historical Volatility 47.92%
  • IV Percentile 69%
  • IV Rank 30.71%
  • IV High 64.57% on 11/11/25
  • IV Low 20.32% on 08/21/25
  • Expected Move (DTE 29) 4.12 (7.58%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 48
  • Volume Avg (30-Day) 823
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 24,522
  • Open Int (30-Day) 23,048
  • Expected Range 50.26 to 58.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.62
  • Number of Estimates 7
  • High Estimate 0.62
  • Low Estimate 0.61
  • Prior Year 0.64
  • Growth Rate Est. (year over year) -3.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.07 +17.86%
on 01/20/26
57.81 -6.08%
on 01/20/26
+5.83 (+12.02%)
since 12/22/25
3-Month
45.07 +20.47%
on 11/07/25
57.81 -6.08%
on 01/20/26
+3.14 (+6.14%)
since 10/22/25
52-Week
39.61 +37.08%
on 03/04/25
57.81 -6.08%
on 01/20/26
+3.14 (+6.14%)
since 01/22/25

Most Recent Stories

More News
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4...

QGEN : 54.65 (-1.81%)
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028

QGEN : 54.65 (-1.81%)
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return...

QGEN : 54.65 (-1.81%)
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 ...

QGEN : 54.65 (-1.81%)
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven...

QGEN : 54.65 (-1.81%)
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

Parse Biosciences is a fast-growing innovator in single-cell sample preparation, with technologies used in more than 3,000 labs across over 40 countries ...

QGEN : 54.65 (-1.81%)
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA Workflow...

QGEN : 54.65 (-1.81%)
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers ...

QGEN : 54.65 (-1.81%)
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date / time: Tuesday, November 4 ...

QGEN : 54.65 (-1.81%)
Qiagen N.V. Announces Voting Rights Notification by AFM

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Qiagen (...

QGEN : 54.65 (-1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed...

See More

Key Turning Points

3rd Resistance Point 58.29
2nd Resistance Point 57.00
1st Resistance Point 56.33
Last Price 54.65
1st Support Level 54.37
2nd Support Level 53.08
3rd Support Level 52.41

See More

52-Week High 57.81
Last Price 54.65
Fibonacci 61.8% 50.86
Fibonacci 50% 48.71
Fibonacci 38.2% 46.56
52-Week Low 39.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar